About ExoCR
ExoCR is an advanced exosome-based biologic developed by Cartessa Aesthetics, designed to enhance regenerative aesthetic treatments. This product is formulated to improve skin rejuvenation and recovery, particularly when used in conjunction with procedures like microneedling and laser resurfacing.
ExoCR –
Next-Generation Exosome Therapy for Skin Renewal
ExoCR is a
high-potency exosome-rich biologic designed to enhance skin regeneration and
optimize outcomes following in-office aesthetic procedures. Sourced from
Wharton’s Jelly of the umbilical cord, ExoCR delivers over 10 billion intact,
single-source exosomes per vial, alongside more than 1,000 growth factors,
peptides, cytokines, and extracellular vesicles. Its non-lyophilized
formulation preserves the full bioactivity of the exosomes, ensuring immediate
efficacy upon application.
Applied topically
after treatments such as microneedling, laser resurfacing, or RF, ExoCR
accelerates healing, reduces inflammation, and stimulates dermal remodeling for
visibly smoother, firmer, and more radiant skin. Clinicians report enhanced
results with reduced downtime, making ExoCR an ideal companion for advanced
skin rejuvenation protocols.
Cartessa Aesthetics is
a U.S.-based leader in aesthetic device distribution and biologic innovation.
The company partners with top-tier manufacturers and labs to bring advanced,
science-backed solutions to medical aesthetic professionals across North America.
With a strong focus on safety, efficacy, and clinical performance, Cartessa has
become a trusted name in regenerative skincare and post-procedural enhancement.